Sansure Biotech Inc
Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tr… Read more
Sansure Biotech Inc (688289) - Net Assets
Latest net assets as of September 2025: CN¥7.22 Billion CNY
Based on the latest financial reports, Sansure Biotech Inc (688289) has net assets worth CN¥7.22 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥9.46 Billion) and total liabilities (CN¥2.24 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥7.22 Billion |
| % of Total Assets | 76.29% |
| Annual Growth Rate | 52.72% |
| 5-Year Change | 54.8% |
| 10-Year Change | N/A |
| Growth Volatility | 257.79 |
Sansure Biotech Inc - Net Assets Trend (2017–2024)
This chart illustrates how Sansure Biotech Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sansure Biotech Inc (2017–2024)
The table below shows the annual net assets of Sansure Biotech Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥7.35 Billion | -1.07% |
| 2023-12-31 | CN¥7.42 Billion | -1.17% |
| 2022-12-31 | CN¥7.51 Billion | +17.73% |
| 2021-12-31 | CN¥6.38 Billion | +34.47% |
| 2020-12-31 | CN¥4.75 Billion | +751.23% |
| 2019-12-31 | CN¥557.48 Million | +40.67% |
| 2018-12-31 | CN¥396.29 Million | +4.56% |
| 2017-12-31 | CN¥378.99 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sansure Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 520728754128.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥4.90 Billion | 67.65% |
| Common Stock | CN¥582.39 Million | 8.04% |
| Other Components | CN¥1.76 Billion | 24.31% |
| Total Equity | CN¥7.24 Billion | 100.00% |
Sansure Biotech Inc Competitors by Market Cap
The table below lists competitors of Sansure Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
OceanaGold Corporation
PINK:OCANF
|
$699.09 Million |
|
Northern Dynasty Minerals Ltd
NYSE MKT:NAK
|
$699.95 Million |
|
Shanghai Smith Adhesive New
SHG:603683
|
$700.16 Million |
|
San Miguel AG
BA:SAMI
|
$700.38 Million |
|
Jiangsu Gian Technology Co Ltd
SHE:300709
|
$699.02 Million |
|
Shenzhen Injoinic Technology Co. Ltd. A
SHG:688209
|
$698.92 Million |
|
MLOptic Corp. A
SHG:688502
|
$698.89 Million |
|
Shandong Dawn Polymer Co Ltd
SHE:002838
|
$698.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sansure Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,201,271,019 to 7,243,225,866, a change of 41,954,847 (0.6%).
- Net income of 275,596,151 contributed positively to equity growth.
- Dividend payments of 268,401,272 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥275.60 Million | +3.8% |
| Dividends Paid | CN¥268.40 Million | -3.71% |
| Other Changes | CN¥34.76 Million | +0.48% |
| Total Change | CN¥- | 0.58% |
Book Value vs Market Value Analysis
This analysis compares Sansure Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.49x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 17.31x to 1.49x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥1.06 | CN¥18.28 | x |
| 2018-12-31 | CN¥1.10 | CN¥18.28 | x |
| 2019-12-31 | CN¥0.94 | CN¥18.28 | x |
| 2020-12-31 | CN¥8.02 | CN¥18.28 | x |
| 2021-12-31 | CN¥10.76 | CN¥18.28 | x |
| 2022-12-31 | CN¥12.96 | CN¥18.28 | x |
| 2023-12-31 | CN¥12.28 | CN¥18.28 | x |
| 2024-12-31 | CN¥12.30 | CN¥18.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sansure Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.80%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.90%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.19x
- Recent ROE (3.80%) is below the historical average (16.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -2.81% | -4.74% | 0.40x | 1.49x | CN¥-48.55 Million |
| 2018 | 1.71% | 2.23% | 0.55x | 1.39x | CN¥-32.87 Million |
| 2019 | 7.08% | 10.80% | 0.57x | 1.15x | CN¥-16.27 Million |
| 2020 | 55.14% | 54.94% | 0.87x | 1.15x | CN¥2.14 Billion |
| 2021 | 35.21% | 49.68% | 0.64x | 1.11x | CN¥1.61 Billion |
| 2022 | 25.82% | 30.03% | 0.70x | 1.22x | CN¥1.19 Billion |
| 2023 | 5.05% | 36.12% | 0.12x | 1.17x | CN¥-356.41 Million |
| 2024 | 3.80% | 18.90% | 0.17x | 1.19x | CN¥-448.73 Million |
Industry Comparison
This section compares Sansure Biotech Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,246,530,775
- Average return on equity (ROE) among peers: 12.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sansure Biotech Inc (688289) | CN¥7.22 Billion | -2.81% | 0.31x | $699.08 Million |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $2.03 Billion | -9.26% | 2.64x | $356.80 Million |
| Blue Sail Medical Co Ltd (002382) | $10.54 Billion | 10.97% | 0.61x | $763.05 Million |
| Andon Health Co Ltd (002432) | $758.75 Million | 1.34% | 0.32x | $2.12 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $2.75 Billion | 15.67% | 0.82x | $346.13 Million |
| Guangzhou Improve Med Instrument (300030) | $592.55 Million | 4.90% | 0.10x | $234.74 Million |
| Shanghai Tofflon Science Tech (300171) | $2.41 Billion | 11.06% | 0.57x | $784.88 Million |
| Truking Technology Ltd (300358) | $320.32 Million | 29.77% | 1.35x | $545.42 Million |
| Jiangxi Sanxin Medtec Co Ltd (300453) | $1.41 Billion | 16.14% | 0.58x | $438.45 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $1.55 Billion | 13.64% | 0.15x | $1.62 Billion |
| Autek China Inc (300595) | $105.24 Million | 28.59% | 0.10x | $1.21 Billion |